title: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
abstract: BACKGROUND
  To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Thirty-six chemotherapy-naïve patients with NSCLC received 500 mg/m2 MTA plus 75 mg/m2 cisplatin every 21 days, with 4 mg dexamethasone orally twice daily on the day before, of, and after MTA administration.
  
  
  RESULTS
  Median age was 58 years. WHO performance status was 0-2. Eighteen patients each had stage IIIB and IV disease. Seventeen patients each had squamous-cell and adenocarcinoma; two had undifferentiated disease. Fourteen patients (39%; 95% confidence interval: 23%-57%) showed partial response; seventeen (47%) had stable disease. Median survival was 10.9 months. Twenty-one patients (59%) experienced grade 3 or 4 granulocytopenia without fever or infection. Five (14%) and six (17%) patients experienced grade 3 anemia and grade 3 or 4 thrombocytopenia, respectively. Nonhematological toxicities included grade 3 nausea in two patients (6%), and grade 3 and 4 diarrhea in one patient (3%) each. One patient each experienced grade 4 ALT and grade 3 bilirubin and AST elevations.
  
  
  CONCLUSIONS
  MTA plus cisplatin is well tolerated and active against NSCLC. Further studies of this combination are warranted.
authors.affiliation: Thoraxklinik Heidelberg GmBH, Germany. manegold@rno.de
authors.forename: C
authors.initials: C
authors.lastname: Manegold
authors.forename: U
authors.initials: U
authors.lastname: Gatzemeier
authors.forename: J
authors.initials: J
authors.lastname: von Pawel
authors.forename: R
authors.initials: R
authors.lastname: Pirker
authors.forename: R
authors.initials: R
authors.lastname: Malayeri
authors.forename: J
authors.initials: J
authors.lastname: Blatter
authors.forename: K
authors.initials: K
authors.lastname: Krejcy
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D003907:Dexamethasone; D002945:Cisplatin